Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Immunology Pavlos > Clinical and Pathological Features of Immune-Mediated Inflammatory Diseases and Approved Treatments > Flashcards

Clinical and Pathological Features of Immune-Mediated Inflammatory Diseases and Approved Treatments Flashcards

1
Q

Genetic characteristics RA

A

• MHC class II (DR4)
• PTPN22, CTLA4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Conventional anchor drug
RA

A

MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Genetic characteristics CD

A

• MHC class II (DRB1)
• Interleukin-23R, NOD2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Conventional anchor drug
CD

A

AZT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Conventional anchor drug
UC

A

Cyclosporin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Genetic characteristics UC

A

• MHC class II (DRB1)
• Interleukin-23R, interleukin-10R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Genetic characteristics Axial spondylarthritis

A

• MHC class I (B27)
• Interleukin-23R, ERAP1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Conventional anchor drug
Axial spondylarthritis

A

Sulfasalazin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Genetic characteristics psoriatic arthritis

A

• MHC class I (C06)
• Interleukin-23R, A20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Conventional anchor drug
psoriatic arthritis

A

MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drivers RA

A

Autoimmunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drivers CD

A

Microbial dysbiosis and barrier dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drivers UC

A

Microbial dysbiosis and barrier dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drivers axial spondylarthritis

A

Mechanical stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drivers psoriatic arthritis

A

Mechanical stress and metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Key pathological process RA

A

Synovitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Key pathological process
CD

A

Granuloma formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Key pathological process UC

A

Cryptitis and goblet-cell loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Key pathological process
Axial spondylarthritis

A

Axial enthesitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Key pathological process
Psoriatic arthritis

A

Enthesitis and synovitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Key associated disease RA

A

Interstitial lung disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Key associated disease CD

A

Erythema nodosum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Key associated disease UC

A

PSC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Key associated disease Axial Spondyloarthritis

A

Anterior uveitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Key associated disease Psoriatic arthritis

26
Q

NSAID responsiveness RA

27
Q

Glucocorticoid responsiveness RA

28
Q

NSAID responsiveness CD

29
Q

Glucocorticoid responsiveness CD

30
Q

NSAID responsiveness UC

31
Q

Glucocorticoid responsiveness UC

32
Q

NSAID responsiveness Axial spondylarthritis

33
Q

Glucocorticoid responsiveness Axial spondylarthritis

34
Q

NSAID responsiveness psoriatic arthritis

35
Q

Glucocorticoid responsiveness psoriatic arthritis

36
Q

Cellular immune response RA

A

B cells, Tph or Tfh cells, macrophages, fibroblasts

37
Q

Cellular immune response CD

A

Th1/Th17 cells, dendritic cells, macrophages

38
Q

Cellular immune response UC

A

Th2/Th9/Th17 cells, neutrophils

39
Q

Cellular immune response axial spondylarthritis

A

Th17 cells, T γ/δ cells, ILC3, neutrophils

40
Q

Cellular immune response
psoriatic arthritis

A

Th17 cells, T γ/δ cells, ILC3, neutrophils, fibroblasts

41
Q

Approved TNF-α inhibitors RA

A

Adalimumab, certolizumab, etanercept, golimumab, infliximab

42
Q

Approved TNF-α inhibitors CD

A

Adalimumab, certolizumab (U.S.), infliximab

43
Q

Approved TNF-α inhibitors UC

A

Adalimumab, certolizumab (U.S.), golimumab, infliximab

44
Q

Approved TNF-α inhibitors Axial spondylarthritis

A

Adalimumab, certolizumab, etanercept, golimumab, infliximab

45
Q

Approved TNF-α inhibitors psoriatic arthritis

A

Adalimumab, certolizumab, etanercept, golimumab, infliximab

46
Q

Approved cytokine signature drugs (targets) RA

A

Tocilizumab (IL-6R), sarilumab (IL-6R)

47
Q

Approved cytokine signature drugs (targets) CD

A

Ustekinumab (IL-12/23)

48
Q

Approved cytokine signature drugs (targets) UC

A

Ustekinumab (IL-12/23)

49
Q

Approved cytokine signature drugs (targets) Axial spondylathtitis

A

Secukinumab (IL-17A), ixekizumab (IL-17A)

50
Q

Approved cytokine signature drugs (targets) psoriatic arthritis

A

Secukinumab (interleukin-17A),
ixekizumab (IL-17A),
ustekinumab (IL-12/23),
guselkumab (p19, IL-23)

51
Q

Other approved targeted therapies RA

A

Abatacept, rituximab

52
Q

Other approved targeted therapies CD

A

Vedolizumab

53
Q

Other approved targeted therapies UC

A

Vedolizumab

54
Q

Other approved targeted therapies axial spondylathritis

55
Q

Other approved targeted therapies psoriatic arthritis

A

Apremilast, abatacept

56
Q

Approved JAK inhibitors RA

A

Tofacitinib, baricitinib, upadacitinib, filgotinib (E.U.)

57
Q

Approved JAK inhibitors CD

58
Q

Approved JAK inhibitors UC

A

Tofacitinib

59
Q

Approved JAK inhibitors axial spondylarthritis

A

Upadacitinib (E.U.)

60
Q

Approved JAK inhibitors psoriatic arthritis

A

Tofacitinib, upadacitinib (E.U.)

Immunology Pavlos (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions